Novavax completes process for WHO emergency use approval of COVID-19 vaccine

Vaccine developer Novavax Inc said on Thursday it has completed the submission process for emergency use listing of its COVID-19 vaccine candidate with the World Health Organization. The company submitted to the health agency all modules required for the evaluation of NVX-CoV2373, its protein-based COVID-19 vaccine, days after receiving its first emergency use authorization from Indonesia. 'The first authorization of the COVID-19 vaccine... will fill a vital need for Indonesia, which is the fourth most populous nation on earth and continues to work to procure sufficient vaccine for its population,' Chief Executive Stanley Erck said during an investor call.